Rina Lokaj
Articles
Adjuvant Nivolumab Falls Short of Disease-Free Survival End Point in Locally Advanced High-Risk RCC
January 27th 2024In the phase 3 CheckMate 914 trial, the use of nivolumab did not meet the primary endpoint of disease-free survival when compared to a placebo in patients with localized renal cell carcinoma at a heightened risk of relapse following nephrectomy.
Optimal Outcomes: Nivolumab Plus Chemotherapy Boosts Survival Rates
January 18th 2024In patients who were administered nivolumab in conjunction with chemotherapy, there were enhancements observed in both overall survival and progression-free survival compared to those who received chemotherapy alone.
Brentuximab Combo Demonstrates Positive Efficacy in Advanced Hodgkin Lymphoma
December 11th 2023Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine appears to be well tolerated in patients with advanced stage classical Hodgkin lymphoma, according to data from the phase 2 SGN35-027 trial.
Axi-cel Improves OS vs SOC in Older Patients With Large B-Cell Lymphoma
December 10th 2023Results from the phase 3 ZUMA-7 trial showed superior progression-free survival and overall survival in patients 65 and older with large B-cell lymphoma with axicabtagene ciloleucel compared with standard of care.
T-DXd Shows Early Survival Advantage in Advanced Breast Cancer and Leptomeningeal Carcinomatosis
December 7th 2023Early findings from the DEBBRAH study suggest that fam-trastuzumab deruxtecan-nxki shows potential in treating patients with advanced HER2-positive, HER2-low breast cancer, including those with leptomeningeal carcinomatosis.
